All Vyluma Articles
-
703Latest Myopia NewsVyluma Receives EU Marketing Application Authorization for Low-Dose Atropine NVK002
May 29, 2024 BRIDGEWATER, N.J. — Vyluma announced it has received approval from the European Medicines Agency (EMA) of its Marketing Authorization...
-
1.6KClinicalObstacles with Compounded Low-Dose Atropine
sponsored content November 1, 2023 By Erin S. Tomiyama, OD, PhD, FAAO Most compounding pharmacies are small and do not have the...
-
802Latest Myopia News
Vyluma Releases Four-Year Results From Phase III of CHAMP Study
October 11, 2023 BRIDGEWATER, N.J. — Vyluma has released the results from the second stage of Phase III of its CHAMP (Childhood...
-
2.3KClinicalPediatric Ophthalmologists Dive Deep on Low-Dose Atropine for Myopia Management
sponsored content August 15, 2023 By Kristen Dalli, Managing Editor, Review of Myopia Management ‘Pediatric ophthalmologists are the tip of the spear....
-
1.9KResearch ReviewCHAMP Study Three-Year Results
June 15, 2023 By Dwight Akerman, OD, MBA, FAAO, FBCLA, FIACLE In a new study recently published in JAMA Ophthalmology, a novel preservative-free...
-
1.5KLatest Myopia NewsFDA Accepts Vyluma’s New Drug Application for NVK002 Atropine
June 6, 2023 BRIDGEWATER, N.J. — The U.S. Food and Drug Administration (FDA) has accepted Vyluma’s new drug application (NDA) for its...
-
2.6KClinicalThe Ins and Outs of Vyluma’s CHAMP Study
sponsored content June 1, 2023 By Kristen Dalli, Managing Editor, Review of Myopia Management At this year’s Global Specialty Lens Symposium, Mark...
-
1.3KClinicalVyluma’s Navneet Puri and Raul Trillo Discuss CHAMP Study Results
sponsored content November 1, 2022 Review of Myopia Management’s Chief Medical Editor Dwight Akerman, OD, MBA, FAAO, FBCLA, FIACLE, interviewed Vyluma executives...
-
3.7KClinicalVyluma CHAMP Pivotal Phase 3 Clinical Trial Q&A
sponsored content October 27, 2022 Vyluma aims to preserve the vision of a global population by providing meaningful and effective pharmaceutical ophthalmic...
-
1.5KLatest Myopia NewsVyluma Checks Off Last Patient Visit for NVK002 Clinical Trial
September 1, 2022 BRIDGEWATER, N.J. — Vyluma has checked off an important step in its Phase III CHAMP (Childhood Atropine for Myopia...
-
2.1KLatest Myopia NewsVyluma and Laboratories Théa Enter Licensing Agreement for NVK002
June 14, 2022 BRIDGEWATER, N.J. — Vyluma and Laboratories Théa have entered into an exclusive licensing agreement for the registration and commercialization...
-
1.4KClinical
The 2021 Year in Review for Myopia Management
sponsored content January 3, 2022 By Neal Wolff, Vice President and Head of Marketing, Vylmua This year, awareness and understanding of myopia...
-
2.0KLatest Myopia NewsVyluma and MyMyopia.com Announce Plans to Support World Sight Day
October 8, 2021 BRIDGEWATER, NJ — To show support for the International Agency for the Prevention of Blindness‘ (IAPB) 2021 World Sight...
-
3.9KClinicalVyluma: Leading with Innovation
sponsored content October 1, 2021 By Dwight Akerman, OD, MBA, FAAO, FBCLA Vyluma is dedicated to using its deep expertise to develop...
-
2.6KLatest Myopia News
Nevakar Launches New Ophthalmic Company Vyluma
May 25, 2021 BRIDGEWATER, NJ — Nevakar has launched Vyluma, a new company that will create treatments for ophthalmic diseases such as...